A vaccine given during pregnancy is substantially lowering hospital admissions among newborns with respiratory syncytial virus (RSV), with UK health officials confirming a decrease of more than 80 per cent. The jab, offered to pregnant women from 28 weeks of gestation since 2024, protects babies from birth by boosting maternal immunity and passing protection through the placenta. A significant recent study examining nearly 300,000 births across England between September 2024 and March 2025 has demonstrated the vaccine’s “excellent protection” during the timeframe when infants are most vulnerable to the virus. RSV affects roughly 50 per cent of newborns and remains one of the leading causes of hospital admission in babies under one year old, with more than 20,000 serious cases recorded annually across the UK.
How the immunisation safeguards at-risk babies
RSV, or respiratory syncytial virus, is a common respiratory infection that affects roughly half of all newborns during their first few months of life. The virus can range from causing mild cold-like symptoms to causing severe chest infections that leave babies struggling to breathe and feed. In the most severe cases, the inflammation in the lungs becomes life-threatening, with small numbers of babies dying from the infection annually. Dr Conall Watson, national programme lead for RSV at the UK Health Security Agency, emphasises the distressing nature of serious RSV infections: “In babies with bad infections you can see their chest and lungs working hard, as they try to pull enough oxygen in. This is extremely frightening as a parent, frightening with good reason.”
The pregnancy vaccine works by stimulating the mother’s immune system to generate defence proteins, which are then transferred to the developing baby through the placenta. This maternal immunity provides newborns with instant defence from the moment of birth, exactly when they are highly susceptible to RSV. The latest research shows that protection reaches nearly 85 per cent when the vaccine is given at least four weeks before delivery. Even shorter intervals between vaccination and birth can still deliver meaningful protection, with evidence indicating that a fortnight’s interval is sufficient to shield babies delivered prematurely. Dr Watson recommends pregnant women to have the vaccine on schedule, whilst noting that protection can still occur even if administered later in the third trimester.
- Nearly 85% coverage when vaccinated four weeks before birth
- Maternal antibodies passed through placenta safeguard newborns from day one
- Protection possible with 2-week gap before premature birth
- Vaccination during the third trimester still provides meaningful protection for infants
Compelling evidence from recent research
The effectiveness of the pregnancy RSV vaccine has been established through a thorough investigation undertaken in England, reviewing data from approximately 300,000 babies born between September 2024 and March 2025. This accounts for approximately 90 per cent of all births during that six-month period, providing robust and representative information of the vaccine’s real-world impact. The study’s findings have been supported by the UK Health Security Agency as showing “excellent protection” for newborns during their most vulnerable early months. The scale of this research gives healthcare professionals and expectant parents with trust in the vaccine’s established performance across different groups and contexts.
The results present a striking picture of the vaccine’s protective power. More than 4,500 babies were treated in hospital with RSV throughout the study period, with the great majority being infants whose mothers did not receive the vaccination. This clear distinction underscores the vaccine’s critical role in preventing serious illness in newborns. The drop in hospital admissions exceeding 80 per cent represents a significant public health achievement, helping to prevent thousands of infants from experiencing the alarming and potentially severe symptoms connected with severe RSV infection. These findings strengthen the importance of the vaccination programme launched in the UK in 2024.
Study design and parameters
The research examined birth and hospital admission records from England over a six-month period, capturing data on approximately 90 per cent of all births during this timeframe. By examining nearly 300,000 babies born to vaccinated and unvaccinated mothers, researchers were able to establish direct comparisons of RSV infection rates and hospitalisations. The large sample size and thorough nature of the data collection ensured that findings were statistically robust and reflective of the wider population, rather than individual cases or limited subgroups.
The study specifically tracked hospital admissions for RSV among infants born to mothers who had received the vaccine at differing periods before delivery. This allowed researchers to establish the minimum time required between vaccination and birth for optimal protection, as well as to determine whether protection remained meaningful with reduced timeperiods. The methodology captured practical outcomes rather than laboratory-based settings, providing tangible evidence of how the vaccine functions when delivered across varied healthcare environments and patient circumstances throughout the final three months of pregnancy.
| Key Finding | Impact |
|---|---|
| Nearly 85% protection with four-week vaccination interval | Optimal protection achieved when vaccine given one month before delivery |
| Over 80% reduction in newborn hospital admissions | Thousands of infants prevented from serious RSV-related illness annually |
| Vast majority of hospitalisations in unvaccinated mothers’ babies | Clear evidence of vaccine efficacy in preventing severe infection |
| Protection possible with two-week pre-birth interval | Meaningful safeguard even for early deliveries and shorter vaccination windows |
Understanding RSV and the dangers
Respiratory syncytial virus, typically known as RSV, is one of the leading causes of hospital admission in infants aged under twelve months across the United Kingdom. The virus affects approximately half of all newborns during their first few months of life, with severity varying dramatically from minor cold-type symptoms to severe, life-threatening chest infections. Over 20,000 infants require intensive hospital care for RSV annually in the UK alone, placing considerable pressure on children’s wards and newborn care units during busier periods.
The infection produces inflammation deep within the lungs and airways, making it extremely challenging for affected infants to feed and breathe effectively. Parents often witness their babies fighting for breath, their chests rising whilst they try to pull enough air into their damaged lungs. Whilst most infants recover with supportive care, a small but significant proportion perish from RSV complications each year, making vaccination as prevention a critical public health priority for protecting the youngest and most at-risk individuals in the population.
- RSV triggers inflammation in lungs, resulting in severe breathing difficulties in babies
- Half of all infants catch the infection in their first few months of life
- Symptoms span from mild colds to life-threatening chest infections requiring hospitalisation
- More than 20,000 UK babies need serious hospital treatment for RSV each year
- Few babies succumb to RSV related complications annually in the UK
Adoption rates and expert recommendations
Since the RSV vaccine programme began in 2024, health officials have highlighted the importance of pregnant women getting their jab at the ideal time for peak protection. Dr Conall Watson, lead for the national programme for RSV at the UK Health Security Agency, has emphasised that timing is crucial for ensuring newborns receive the most robust immunity from birth. Whilst the study demonstrates that vaccination performed at least four weeks prior to delivery offers approximately 85% protection, experts recommend women to get their vaccine as early as possible from 28 weeks of pregnancy forward to enhance the antibodies transferred to their babies via the placenta.
The messaging from health authorities stays clear: pregnant women should prioritise getting vaccinated during their third trimester, even if circumstances mean they cannot get vaccinated at the best timing. Dr Watson has reassured expectant mothers that protection is still achievable with reduced timeframes between vaccination and birth, including even a two-week gap for those delivering slightly early. This adaptable strategy acknowledges the realities of pregnancy and childbirth whilst maintaining strong protection for at-risk infants during their most critical early months when RSV represents the highest danger of severe infection.
Regional disparities in immunisation
Whilst the RSV vaccine programme has been rolled out across England, uptake rates and implementation timelines have differed across various areas and NHS trusts. Certain regions have attained greater immunisation rates among eligible pregnant women, whilst others continue working to boost understanding and access to the jab. These regional differences reflect differences across healthcare infrastructure, communication strategies, and local engagement efforts, though the overall statistics demonstrates consistently strong protection irrespective of geographical location.
- NHS trusts launching multiple messaging strategies to reach pregnant women
- Inconsistencies across regions in vaccine uptake rates in different parts of England necessitate strategic intervention
- Regional health providers tailoring initiatives to align with community needs and circumstances
Practical implications and parent viewpoints
The vaccine’s impressive effectiveness provides tangible benefits for families throughout the United Kingdom. With more than 20,000 babies hospitalised annually due to RSV before the launch of this safeguarding intervention, the 80% reduction in admissions means thousands of infants protected against critical disease. Parents no more face the upsetting situation of seeing their babies labour to breathe or struggle to eat, symptoms that mark critical RSV illness. The vaccine has fundamentally shifted the terrain of neonatal breathing health, offering expectant mothers a active means to protect their most vulnerable children during those crucial first weeks.
For families like that of Malachi, whose serious RSV infection caused severe brain damage, the vaccine’s availability carries deep personal significance. His mother’s support of the jab emphasises the life-altering consequences that vaccine-preventable disease can have on young children and their families. Whilst Malachi’s experience precedes the vaccine programme, his story resonates powerfully with parents now provided with protection. The knowledge that such grave complications—hospital stay, oxygen dependency, neurological damage—are now largely avoidable has offered substantial reassurance to pregnant women navigating their third trimester, converting what was once an unavoidable seasonal threat into a manageable risk.